P. Furlong

Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi‐Stakeholder Think Tank

N. Stockbridge, B. McCrindle, J. Newburger, 2018, Journal of the American Heart Association.

The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.

Janzen, A. M. Møller, D. Debanne, 1996, The Canadian journal of cardiology.

Transparency as a Means to Increase Clinical Trial Enrollment

Barbara J. Godlew, P. Furlong, 2010 .

Unmet Therapeutic Needs of Non-Ambulatory Patients with Duchenne Muscular Dystrophy: A Mixed-Method Analysis

Anne L R Schuster, John F. P. Bridges, R. Fischer, 2022, Therapeutic Innovation & Regulatory Science.

Data Sharing Goals for Nonprofit Funders of Clinical Trials (Preprint)

Brian A. Nosek, Lynn D. Hudson, I. Sim, 2020 .

Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?

A. Caplan, H. Lynch, Alison Bateman-House, 2021, The American journal of bioethics : AJOB.

Defining patient centricity with patients for patients and caregivers: a collaborative endeavour

M. Seres, P. Furlong, G. Yeoman, 2017, BMJ Innovations.